Loading market dashboard
Idorsia Ltd
IDRSFHealthcareOTCCH
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial. The glycan target of this vaccine is present on both bacteria and spores – the transmissible form of the pathogen responsible for spreading infection – of the most clinically relevant C. difficile strains, including hypervirulent variants. Following initial results in June 2025, which provided the first clinical validation for Idorsia's synthetic glycan vaccine technology, the company advanced the program with a higher-dose cohort.
Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist, significantly reduces albuminuria and improves albuminuria risk categories in patients with resistant hypertension. The data were presented by Prof. Markus Schlaich at the 35th Congress of the European Society of Hypertension (ESH).
Allschwil, Switzerland – May 6, 2026 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors.
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is being expanded across additional European markets to further accelerate growth Partnering discussions for TRYVIO™/JERAYGO™ are ongoing with several parties Allschwil, Switzerland – April 28, 2026 Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today announced its financial results for the first quarter of 2026.
Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026, at 14.00 CEST at the Congress Center, Messe Basel, Switzerland.
Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Development, effective May 1, 2026. He succeeds Dr Alberto Gimona, who is retiring.
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
Allschwil, Switzerland – March 24, 2026 Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of Shareholders: Natalia Misciattelli, Chief Executive Officer and member of the Board of Directors at AAVantgarde Bio; Gabriel Baertschi, Chief Executive Officer of Grünenthal; and André C. Muller, former Chief Executive Officer of Idorsia.
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti will step down from her role as Chief Executive Officer (CEO).
Allschwil, Switzerland – March 10, 2026 Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridorexant) – its treatment for adults with insomnia – across the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain.
